Dopamine receptor agonists for treating prolactinomas

Expert Opinion on Investigational Drugs

Volumn 11, Issue 6, 2002, Pages 787-800

  Colao, Annamaria ^a   di Sarno, Antonella ^a   Pivonello, Rosario ^a   di Somma, Carolina ^a   Lombardi, Gaetano ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Bromocriptine; Cabergoline; Dopamine agonists; Medical therapy; Prolactin; Prolactinomas

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; HALOPERIDOL; PERGOLIDE; PROLACTIN; QUINAGOLIDE; SULPIRIDE; AMINOQUINOLINE DERIVATIVE; ERGOLINE DERIVATIVE; ERGOT ALKALOID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; BIOCHEMISTRY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG TOLERABILITY; EDEMA; FEMALE; FEVER; FLU LIKE SYNDROME; FLUSHING; GASTROINTESTINAL DISEASE; GENDER; GONAD DYSFUNCTION; HEMATOLOGIC DISEASE; HUMAN; HYPERPROLACTINEMIA; INFERTILITY; LUNG DISEASE; MALE; MENSTRUAL CYCLE; METABOLIC DISORDER; MULTICENTER STUDY; NEUROLOGIC DISEASE; NONHUMAN; NOSE CONGESTION; PREGNANCY; PREGNANCY DISORDER; PROLACTIN RELEASE; PROLACTINOMA; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RAT; REVIEW; SEXUAL DYSFUNCTION; THROMBOEMBOLISM; ANIMAL; DRUG RESISTANCE; HYPOPHYSIS TUMOR; PHYSIOLOGY; SECRETION;

AMINOQUINOLINES; ANIMAL; BROMOCRIPTINE; DOPAMINE AGONISTS; DRUG RESISTANCE, NEOPLASM; ERGOLINES; ERGOT ALKALOIDS; FEMALE; HUMAN; PERGOLIDE; PITUITARY NEOPLASMS; PREGNANCY; PROLACTIN; PROLACTINOMA; ANIMALS; HUMANS;

EID: 0036016090     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.11.6.787     Document Type: Review

References (140)

1. Prolactin: Hyperprolactnemic syndromes and management
2. Spectrum of pituitary disease in multiple endocrine neoplasia Type 1: Clinical, biochemical, and radiological features of pituitary disease in a large MEN 1 kindred
3. Prolactinomas in a large kindred with multiple endocrine neoplasia Type 1: Clinical features and inheritance pattern
4. Subclinical adenoma of the pituitary gland
5. Microadenomas of the pituitary gland and abnormal sellar tomograms in an unselected autopsy series
6. Growth hormone and prolactin excess
7. Prolactinomas in male and female patients: A comparative clinicopathologic study
8. Sex-related difference in the growth of prolactinomas: A clinical and proliferation marker study
9. Management of prolactinomas
10. Management of prolactinomas
11. Transsphenoidal microsurgical therapy of prolactinomas: Initial outcomes and long-term results
12. Treatment of prolactinomas
13. Cabergoline in the treatment of hyperprolactinemia: A study in 455 patients
14. Cabergoline a first choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma
15. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive than in patients pre-treated with other dopamine agonists: A prospective study in 110 patients
16. Cabergoline-induced CSF rhinorrhea in patients with macroprolactinoma. Report of three cases
17. Endoscopic endonasal transphenoidal approach: An addition reason in support of surgery in the management of pituitary lesions
18. Endoscopic endonasal transsphenoidal surgery in recurrent and residual pituitary adenomas: Technical note
19. Medical treatment of prolactinomas
20. Bromocriptine
21. Dopamine agonists and pituitary tumour shrinkage
22. Bromocriptine as primary therapy for prolactin-secreting macroadenomas: Results of a prospective multicenter study
23. Pharmacological characterization of the D-2 dopamine receptor negatively coupled with adenylated cyclase in rat anterior pituitary
24. Dopamine, the dopamine D2 receptor and pituitary tumors
25. Mechanisms of signal transduction at the dopamine D2 receptor
26. D2 Dopaminergic receptors: Normal and abnormal transduction mechanisms
27. Cloning and expression of a rat dopamine D2 receptor cDNA
28. Alternative splicing directs the expression of two D2 dopamine receptor isoforms
29. Structural basis of β-adrenergic receptor function
30. Regions of the al-adrenergic receptor involved in coupling to phosphatidylinositol hydrolysis and enhanced sensitivity of biological function
31. In vitro studies on prolactin release and adenylate cyclase activity in human prolactin-secreting pituitary adenomas. Different sensitivity of macro-and microadenomas to dopamine and vasoactive intestinal polypeptide
32. 2-dopamine receptors
33. Dopaminergic treatments for hyperprolactinemia
34. Inhibitory effects of the dopamine agonists quinagolide (CV 205-502) and bromocriptine on prolactin secretion and growth of SMtTW pituitary tumors in the rat
35. Ergoline derivatives: Receptor affinity and selectivity
36. Endocrine actions of the potent dopamine D2-agonist CV 205-502 and related octrahydrobenzo(g)quinolines
37. Octahydrobenzo[g]quinolines: Potent dopamine agonists which show the relationship between ergolines and apomorphine
38. Resolution and absolute configuration of the potent dopamine agonists N,N-Diethyl-N'-[(3α,4aα,10aβ)-1,2,3,4,4a,5,10,10a, -octahydro-6-hydroxy-1-propyl-3-benzo [g]quinolinyl] sulfamide
39. A novel octahydrobenzo[g]quinoline, CV 205-502, with potent dopamine agonist properties
40. Hormonal effects of CV 205-502, a novel octahydrobenzo[g]quinoline with potent dopamine agonist properties
41. Effects of two novel dopaminergic drugs, CV 205-502 and CQP 201-403, on prolactin and growth hormone secretion by human pituitary tumors in vitro
42. 3H] CV 205-502
43. Recovery of growth hormone secretion following cabergoline treatment of macroprolactinomas
44. Bromocriptine-induced mania?
45. Mental disorders from low-dose bromocriptine
46. Psychotic reactions during treatment of pituitary tumors with dopamine agonist
47. Recurrent myocardial infarction in a postpartum patient receiving bromocriptine
48. Postpartum hypertension, seizures, strokes reported with bromocriptine
49. Severe leukopenia and mild thrombocytopenia after chronic bromocriptine (CB154) administration
50. Bromocriptine-associated hyponatraemia in cirrhosis
51. Management of pituitary tumors
52. Low doses of dopamine agonists in the long-term treatment of macroprolactinomas
53. Effect of dopamine agonist withdrawal after long-term therapy in prolactinomas. Studies with high-definition computerized tomography
54. Long-term treatment of hyperprolactinemia with bromocriptine: Effect of drug withdrawal
55. Withdrawal of bromocriptine after long-term therapy for macroprolactinomas: Effect on plasma prolactin and tumor size
56. Diagnosis and management of hormone-secreting pituitary adenomas
57. Perivascular fibrosis in prolactinomas: Is it increased by bromocriptine?
58. A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation
59. Side effects of bromocriptine
60. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhoea
61. Drugs stimulation dopamine receptors
62. Dopaminergic antiparkinsonian agents
63. In vivo effect of cabergoline, a dopamine agonist, on estrogen-induced rat pituitary tumors
64. Effect of cabergoline, a dopamine agonist, on estrogen-induced rat pituitary tumors: In vitro culture studies
65. Effects on pseudo-pregnancy, pregnancy and interoestrous intervals of pharmacological suppression of prolactin secretion in female dogs and cats
66. Abortion induction in the cat using prostaglandin f2 alpha and a new anti-prolactinic agent cabergoline
67. Selective and extremely long inhibition of prolactin release in man by 1-ethyl-3-(3′-dimethylaminopropyl)-3-(6′ allylergoline-8′-b-carbonyl)urea-diphosphate (fce 21336)
68. Pharmacokinetics, pharmacodynamics, and tolerability of cabergoline, a prolactin-lowering drug, after administration of increasing oral doses (0.5, 1.0, and 1.5 milligrams) in healthy male volunteers
69. Dose related prolactin-inhibitory effect of the new longacting dopamine receptor agonist cabergoline in normal cycling, puerperal and hyperprolactinemic women
70. Effectiveness and tolerability of long-term treatment with cabergoline, a new-lasting ergoline derivative, in hyperprolactinemic patients
71. Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients
72. The efficacy and tolerability of long-term cabergoline therapy in hyperprolactinemic disorders: An open, uncontrolled, multicentre study
73. Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline
74. Treatment of macroprolactinoma with cabergoline: A study of 85 patients
75. Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage
76. Cabergoline
77. Cabergoline. A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinaemia and inhibition of lactation
78. Cabergoline therapy of a large prolactinoma in a bromocriptine-intolerant patient
79. Prevention of puerperal lactation by a single oral administration of the new prolactin-inhibiting drug cabergoline
80. Pleuropulmonary disease associated with dopamine agonist therapy
81. Pleuropulmonary changes during treatment of Parkinson's disease with a long-acting ergot derivative, cabergoline
82. Constrictive pericarditis and pleuropulmonary disease linked to ergot dopamine agonist therapy (cabergoline) for Parkinson's disease
83. Pituitary diseases in pregnancy
84. Management of prolactinomas during pregnancy
85. Outcome of pregnancy in women with treated or untreated hyperprolactinemia
86. Cabergoline animal reproductive toxicity
87. Pregnancy outcome after treatment with the ergot derivative, cabergoline
88. Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: A comparison with bromocriptine
89. Decreased bone density in amenorrheic women
90. Increase in bone mass after treatment of hyperprolactinemic amenorrhea
91. Symptomatic osteoporosis in a man with hyperprolactinemic hypogonadism
92. Importance of gonadal steroids to bone mass in men with hyperprolactinemic hypogonadism
93. Prolactinoma in 53 men: Clinical characteristics and modes of treatment
94. Bone markers and bone density responses to dopamine agonist therapy in hyperprolactinemic males
95. Prolactinomas in children and adolescents: Persistent bone loss after 2 years of prolactin normalization
96. Cabergoline: A new drug for the treatment of hyperprolactinaemia
97. Long-term treatment with cabergoline a new long-lasting ergoline derivative in idiopathic or tumorous hyperprolactinemia and outcome of drug-induced pregnancy
98. The safety of physiological estrogen plus progestin replacement therapy and with oral contraceptive therapy in women with pathological hyperprolactinemia
99. Visual loss in pregnant women with pituitary adenomas
100. Effects of new dopaminergic agonist CV 205-502 on plasma PRL levels and tumor size in BRC-resistant prolactinomas
101. The effects of CV 205-502 in patients with hyperprolactinemia intolerant and/or resistant to bromocriptine
102. Effects of dopamine agonists CV 205-502 in human prolactinomas resistant to bromocriptine
103. Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine
104. Resistance to bromocriptine in prolactinomas
105. Decreased expression of two D2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas
106. In vivo visualization of pituitary dopaminergic receptors by iodine-123 methoxibenzamide (IBZM) correlates with sensitivity to dopamine agonists in two patients with macroprolactinomas
107. Dopamine D2 receptor imaging in pituitary adenomas using Iodine-123-Epidepride and SPECT
108. 123I-methoxybenzamide with hormone levels and tumor size response to quinagolide in patients with pituitary adenomas
109. Hormone levels and tumor size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically nonfunctioning pituitary adenomas: Predictive value of pituitary scintigraphy with 123I-Methoxybenzamide
110. Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage
111. Quinagolide efficacy and tolerability in hyperprolactinemic patients who are resistant to or intolerant of bromocriptine
112. Clinical response and prolactin concentration in hyperprolactinemic women during and after treatment for 24 months with the new dopamine agonist, CV 205-502
113. Effect of Cv 205-502 in hyperprolactinemic patients intolerant to bromocriptine
114. Late development of resistance to bromocriptine in a patient with macroprolactinoma
115. Shrinkage of a PRL-secreting pituitary macroadenoma resistant to cabergoline
116. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: Prevalence, clinical definition and therapeutic strategy
117. Prolactinomas in children and adolescents. Clinical presentation and long term follow-up
118. Hyperprolactinaemia and pituitary adenomas in adolescence
119. Pituitary adenomas in children and adolescents. Clinical presentation, diagnosis and therapeutical strategies
120. Influence of age on the clinical presentation of prolactinomas in male patients
121. Microprolactinomas: Why requiem for surgery?
122. The effect of quinagolide and cabergoline, two selective dopamine receptor type-2 agonists, in the treatment of prolactinomas
123. CV 205-502 treatment of hyperprolactinemia
124. Treatment of prolactin-secreting pituitary macroadenomas with the long-acting non-ergot dopamine agonist CV 205-502
125. A double-blind study comparing a new non-ergot, long-acting dopamine agonist, CV 205-502, with bromocriptine in women with hyperprolactinemia
126. CV 205-502 treatment of macroprolactinomas
127. The efficacy and tolerability of CV 205-502 (a nonergot dopaminergic drug) in macroprolactinoma patients and in prolactinoma patients intolerant to bromocriptine
128. CV 205-502, a new dopamine agonist, versus bromocriptine in the treatment of hyperprolactinemia
129. Acute and long-term effects of once daily oral bromocriptine and a new long-acting non-ergot dopamine agonist, quinagolide, in the treatment of hyperprolactinemia: A double blind study
130. A cross-over study with the two novel dopaminergic drugs cabergoline and quinagolide in hyperprolactinemic patients
131. Pergolide mesylate: Its effects on circulating anterior pituitary hormones in man
132. Potent 48 hours inhibition of prolactin secretion by pergolide in hyperprolactinemic women
133. Pergolide for the treatment of pituitary tumors secreting prolactin or growth hormone
134. Pergolide, a potent long-acting dopamine receptor agonist
135. The long-acting dopamine agonist pergolide mesylate for treatment of hyperprolactinemia
136. Comparison of the clinical activity of mesulergine and pergolide in the treatment of hyperprolactinemia
137. Long-term pergolide treatment of hyperprolactinemic patients previously unsuccessfully treated with dopaminergic drugs
138. Discordant responses of prolactinoma to two different dopamine agonists
139. A comparison of the efficacy and safety of pergolide and bromocriptine in the treatment of hyperprolactinemia
140. Reduction in size of prolactin-secreting tumours in men treated with pergolide